M. Lorenzi

发表

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.

S. Pang, G. Trainor, M. Poss, 2009, Bioorganic & medicinal chemistry letters.

Expression cloning, developmental expression and chromosomal localization of fibroblast growth factor-8.

S. Aaronson, T. Miki, M. Lorenzi, 1995, Oncogene.

Homocysteine exerts cell type-specific inhibition of AP-1 transcription factor.

J. Blumberg, R. Day, M. Lorenzi, 2000, Free radical biology & medicine.

Nerve growth factor regulation of choline acetyltransferase gene expression in rat embryo basal forebrain cultures

F. Hefti, M. Lorenzi, B. Knusel, 1992, Neuroscience Letters.

Selective retinoids and rexinoids in cancer therapy and chemoprevention.

V. Vivat-Hannah, M. Lorenzi, F Christopher Zusi, 2002, Drug discovery today.

Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel).

M. Gottardis, P. LaPointe, V. Vivat-Hannah, 2001, Cancer research.

Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations

T. Miki, M. Lorenzi, P. Castagnino, 1997, Oncogene.

Identification of a novel activated form of the keratinocyte growth factor receptor by expression cloning from parathyroid adenoma tissue

K. Sakaguchi, T. Miki, M. Lorenzi, 1999, Oncogene.

9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.

J. Tokarski, G. Trainor, J. Sack, 2015, Bioorganic & medicinal chemistry letters.

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Italo Poggesi, Vineet Pande, James P. Edwards, 2017 .

Janus Kinase 2 (JAK2) Inhibitors for the Treatment of Myeloproliferative Neoplasm (MPN)

M. Lorenzi, A. Purandare, L. Lombardo, 2010 .

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Andrew H. Beck, A. Khosla, A. Beck, 2019, Cancer Immunology Research.

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Xiaoyan Jiang, M. Lorenzi, Hanyang Lin, 2014, Oncotarget.

Assignment1 of the Ect2 protooncogene to mouse chromosome band 3B by in situ hybridization

S. Takai, T. Miki, M. Lorenzi, 1998, Cytogenetic and Genome Research.

Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors

S. Werner, M. Lorenzi, D. Bottaro, 2000, Oncogene.

Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.

M. Lorenzi, L. Potter, C. A. Ferrendelli, 1989, Molecular pharmacology.

Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.

J. Lu, M. Lorenzi, D. Liu, 2001, Oncogene.

Ostip2, a novel oncoprotein that associates with the Rho exchange factor Ost.

T. Miki, T. Tatsumoto, R. Blumenthal, 2001, DNA and cell biology.

Cooperative transformation of NIH3T3 cells by Gα12 and Rac1

A. Chan, M. Lorenzi, R. Sáez, 1997, Oncogene.

The RIP‐like kinase, RIP3, induces apoptosis and NF‐κB nuclear translocation and localizes to mitochondria

M. Lorenzi, B. Gomes, Derong Liu, 2000, FEBS letters.

Synthetic Lethality of Retinoblastoma Mutant Cells in the Drosophila Eye by Mutation of a Novel Peptidyl Prolyl Isomerase Gene

F. Chen, M. Belvin, L. M. Young, 2005, Genetics.

Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.

L. Wang, J. Pierce, Y. Wu, 1996, Oncogene.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

P. Ross-Macdonald, K. McIntyre, G. Trainor, 2012, Leukemia.

Two mRNAs are transcribed from the human gene for choline acetyltransferase.

M. Lorenzi, W. L. Strauss, A. Trinidad, 1992, DNA and cell biology.

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Bie M. P. Verbist, U. Philippar, T. Graubert, 2021, Molecular Cancer Therapeutics.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

Identification of novel functional inhibitors of 17β‐hydroxysteroid dehydrogenase type III (17β‐HSD3)

I. Takenaka, B. Fink, M. Salvati, 2005 .

Human FRAG1 encodes a novel membrane-spanning protein that localizes to chromosome 11p15.5, a region of frequent loss of heterozygosity in cancer.

C. Keck, T. Miki, M. Lorenzi, 1999, Genomics.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

C. Murray, J. Vialard, D. Newell, 2017, Molecular Cancer Therapeutics.

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

S. Heo, S. Lim, B. Cho, 2020, Cancer discovery.

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

P. Parren, M. Chiu, L. Luistro, 2016, Cancer research.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

P. Zarrinkar, K. Yu, D. Brehmer, 2018, Cell.

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Ying Cheng, Yi-long Wu, C. Moy, 2019, Nature Communications.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

I. Takenaka, B. Fink, M. Salvati, 2005, The Prostate.

Rho exchange factor ECT2 is induced by growth factors and regulates cytokinesis through the N‐terminal cell cycle regulator‐related domains

J. Rubin, T. Miki, T. Tatsumoto, 2003, Journal of cellular biochemistry.